GVS (GVS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
11 Nov, 2026Executive summary
9M 2026 revenue was €329.9m, up 6.4% at constant FX; Q3 revenue was €114.8m, with organic growth accelerating to 13.2%.
Adjusted EBITDA rose 9.0% to €85.8m, with a 26.0% margin; adjusted net profit excluding FX effects was €37.5m, up 3.3%.
Net financial position was €253.5m at 30 September 2026, with leverage of 2.2x.
Financial highlights
Revenue increased from €315.6m to €329.9m; 9M organic growth was 6.4%, comprising volume growth of 3.9% and net price growth of 2.6%.
Adjusted EBITDA rose from €78.7m to €85.8m; margin expanded from 24.9% to 26.0%, up 106 bps.
Adjusted EBIT was €58.8m, or 17.8% of sales, versus €55.7m and 17.6%; adjusted D&A increased to €26.2m from €22.6m.
Adjusted net profit excluding FX effects was €37.5m, with an 11.4% margin, versus €36.3m and 11.5%; including FX effects, adjusted net profit was €41.8m versus €20.7m.
Reported net profit was €33.7m versus €9.0m; basic and diluted EPS were both €0.18 versus €0.05.
Outlook and guidance
FY 2026 guidance confirmed: mid-single-digit revenue growth at constant FX and adjusted EBITDA margin expansion of 50–100 bps versus 2025.
FY 2026 leverage is expected near 2.0x; Q4 sales of €113m–€114m would support the 5% organic growth target.
H2 adjusted EBITDA is forecast at €60m–€61m versus €55m in H1; Q4 revenue is expected broadly in line with Q3.
Q4 working-capital plans include reducing inventory and receivables by ~€10m each; year-end net financial position is expected near €225m.
Latest events from GVS
- Sales and adjusted EBITDA advanced as margins recovered and leverage declined.GVS
H2 2023 - Raised guidance targets 5% organic growth, 27% EBITDA margin, and 1.0x leverage by 2028.GVS
Investor update - Revenue and EBITDA margin rose, with strong net profit and confirmed growth guidance.GVS
Q2 2026 - Q1 2026: Revenue €105M, margin up, Healthcare strong, and share buyback announced.GVS
Q1 2026 - Adjusted EBITDA margin rose to 24.9% as net debt increased from M&A and buybacks.GVS
Q3 2025 - Record profitability and margin gains in H1 2025, with strong outlook for H2.GVS
Q2 2025 - Revenue up 3.7%, EBITDA margin 24.3%, leverage 2.30x, led by Healthcare & Safety growth.GVS
Q3 2024 - H1 2024 revenue and margins rose, guidance was raised, and Health & Safety led growth.GVS
H1 2024 - Q1 2025 revenue rose 3.2% to €107.2M, with margin gains and Haemonetics integration.GVS
Q1 2025